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Abstract
Background: Multiple sclerosis (MS) currently requires long-term treatment with disease-modifying drugs, 
administered parenterally up to once daily. The need for regular self-injection can be a barrier to treatment for many 
patients. Autoinjectors can help patients overcome problems or concerns with self-injection and could, therefore, 
improve treatment adherence. This study was performed to assess the suitability of a new electronic device for the 
subcutaneous (sc) administration of interferon (IFN) beta-1a, 44 mcg three times weekly, for relapsing MS.
Methods: In this Phase IIIb, multicentre, single-arm study, patients with relapsing MS who had been consistently self-
injecting sc IFN beta-1a using an autoinjector for at least 6 weeks were taught to use the new device and self-
administered treatment for 12 weeks thereafter. Patient-rated suitability of the device was assessed at the end of Week 
12 using the Patient User Trial Questionnaire. Patient satisfaction with, and evaluation of, the injection process was 
assessed using the MS Treatment Concern Questionnaire. Trainers evaluated the device using the Trainer User Trial 
Questionnaire.
Results: At Week 12, 71.6% (73/102) of patients considered the device 'very suitable' or 'suitable' for self-injection; 
92.2% (94/102) reported some degree of suitability and only 7.8% (8/102) found the device 'not at all suitable'. At 
Weeks 4, 8 and 12, most patients reported that injection preparation and clean-up, performing injections and ease of 
device use in the previous 4 weeks compared favourably with, or was equivalent to, their previous experience of self-
injection. Injection-related pain, injection reactions and 'flu-like' symptoms remained stable over the 12 weeks. Each 
device feature was rated 'very useful' or 'useful' by at least 80% of patients. All trainers and 95.2% (99/104) of patients 
found device functions 'very easy' or 'easy' to use. Overall convenience was considered the most important benefit of 
the device.
Conclusions: Most patients considered the new electronic injection device suitable for the sc injection of IFN beta-1a. 
They found the device easy to use with useful features, and reported benefits such as overall convenience. The device 
may, therefore, increase treatment adherence in patients with MS, particularly those with injection-related issues.
Trial registration: NCT00735007
Background
Multiple sclerosis (MS) is a chronic, inflammatory and
degenerative disease of the central nervous system that
can cause a wide range of debilitating symptoms affecting
both mental and physical functions [1]. Although MS
remains incurable, treatment with disease-modifying
drugs (DMDs) such as interferon (IFN) beta-1a, IFN
beta-1b and glatiramer acetate can reduce the frequency
of disease exacerbations and may delay disability progres-
sion [2-5]
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Currently, all approved first-line DMDs require fre-
quent, parenteral administration (up to once daily). Due
to the relatively early age of onset and chronic nature of
MS, long-term treatment is often required. Self-injection
is common, but performing regular injections can be
stressful and physically demanding for many patients.
Symptoms of the disease itself, such as poor manual dex-
terity and impaired cognitive function, can make self-
injection more difficult. Other potential issues that may
affect treatment acceptance and, thus, adherence include
needle phobia, concerns about correct injection tech-
niques, perceived lack of efficacy, treatment-related local
and systemic side-effects and treatment fatigue [6-9].
Indeed, non-adherence to MS therapies is a common
problem [10] with clinical consequences including
reduced efficacy [11,12]. Patient education, a good doc-
tor-patient relationship, management of patients' treat-
ment expectations and accurate adherence monitoring
are, therefore, essential to improve treatment adherence.
Mechanical, single-dose injection devices are available
for most DMDs and can help patients to overcome injec-
tion-related issues [13,14]. A new electronic autoinjection
device (RebiSmart™, Merck Serono S.A. - Geneva, Swit-
zerland, an affiliate of Merck KGaA, Darmstadt, Ger-
many) has been developed for the subcutaneous (sc)
administration of IFN beta-1a supplied in a multi-dose
cartridge. The new device is based on an existing device
for administering growth hormone to children (easypod®,
Merck Serono S.A. - Geneva) and has been adapted for
use in patients with MS. The device has features that sim-
plify the injection process and may help patients to over-
come injection-related issues and improve treatment
satisfaction, and may, therefore, increase adherence to
treatment. These features include the convenience of the
multi-dose cartridge, which holds one week's drug dos-
age; easy-to-understand, step-by-step instructions; an
injection log to inform patients of their injection history;
and adjustable comfort settings, which allow patients to
tailor injections to improve comfort. Needle speed and
injection speed, time and depth can all be changed by
patients who experience discomfort upon injection or
who are dissatisfied with the injection process, for exam-
ple because a drop of liquid is seen on the skin when the
needle is withdrawn.
This study was conducted to investigate the feasibility
of using the device for the self-injection of sc IFN beta-1a,
44 mcg three times weekly (tiw), by patients with relaps-
ing MS. To this end, patient-rated suitability of the device
was assessed in a population of patients currently receiv-
ing IFN beta-1a via a single-dose autoinjection device and
in healthcare professionals who trained patients in device
use ('trainers'). The study also assessed patients' satisfac-
tion with the injection process, patients' and trainers'
evaluation of the device, local tolerability and overall
safety.
Methods
Study design
The RebiSmart™ User Trial (study protocol 28733;
NCT00735007) was a Phase IIIb, multicentre, 12-week,
single-arm, open-label study carried out in 15 centres in
Europe, the United States of America and Canada. The
study was carried out in accordance with local clinical
research regulations, approved by local ethics commit-
tees or institutional review boards (IRBs) and conformed
to the World Medical Association Declaration of Helsinki
(1996). A complete listing of the ethics committees that
granted approval for the study is given below:
Canada
IRB services, Ontario; University of British Columbia
Office of Research Services, Clinical Research Ethics
Board, British Columbia.
Germany
Ethik-Kommission der Ärztekammer Hamburg; Ethik-
Kommission bei der Landesärztekammer Baden-Württ-
emberg, Stuttgart; Geschäftsstelle der Ethik-Kommission
des Landes Berlin; Ethik-Kommission der
Landesärztekammer Hessen.
Italy
Comitato di Etica per la Ricerca Biomedica, Università
degli Studi "G. D'Annunzio", Azienda Sanitaria Locale -
Chieti; Comitato Etico Azienda Policlinico Umberto I,
Roma.
Spain
Secretaría Administrativa del Comité Etico de Investiga-
cion Clinica, Hospital Universitario de Bellvitge, Barce-
lona; Comité Ético de Investigación Clínica, Hospital
Clínico San Carlos, Madrid; Comité Ético de Investi-
gación Clínica, Passeig Vall d'Hebrón, Barcelona.
Sweden
Regionala Etikprövningsnämnden i Lund.
USA
Chesapeake Research Review, Inc. Columbia, MD.
Patients
Patients aged 18-65 years with a confirmed diagnosis of
relapsing MS (according to the revised McDonald criteria
[15]) with disease duration of at least 3 months were eligi-
ble. Inclusion criteria required patients to be already
receiving the new formulation of IFN beta-1a that is free
from serum-derived products, 44 mcg sc tiw, adminis-
tered using the Rebiject II™ injection device, and to have
been consistently on therapy for at least 6 weeks prior to
screening. Women could not be pregnant or breastfeed-
ing, and had to be without child-bearing potential. Key
exclusion criteria included receiving any other medica-Devonshire et al. BMC Neurology 2010, 10:28
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tions via injection on a regular basis during the week
prior to the screening period or throughout the study,
receiving any therapy for MS other than sc IFN beta-1a in
the 12 months prior to study enrolment or during the
study, receiving oral or systemic corticosteroids or adre-
nocorticotrophic hormone in the 30 days prior to Study
Day 1 (SD1), inadequate liver function or bone marrow
reserve, moderate or severe renal impairment, a history
of chronic pain syndrome, or any visual or physical
impairment that would preclude the patient from using
the device.
Treatment
Patients self-administered the new formulation of sc IFN
beta-1a, 44 mcg tiw, in a multi-dose cartridge, using the
new electronic device for 12 weeks. The baseline device
'comfort settings' were the same for all patients.
Study procedures and assessments
Patients who met the eligibility criteria during a 2-week
screening period and gave written informed consent were
recruited to the 12-week study. Baseline was defined as
the first day of study drug administration (SD1). At SD1,
patients were taught to self-inject using the new device by
an investigator or a trainer and also underwent a physical
examination. A safety assessment was performed, collect-
ing information on adverse events (AEs) including injec-
tion-site reactions (ISRs), and routine blood samples
were taken for laboratory testing. Patients completed
items 13 to 38 of the Multiple Sclerosis Treatment Con-
cern Questionnaire (MSTCQ) before the first injection
with the new device, and the Patient User Trial Question-
naire after the first injection. They also received a patient
diary and training on the recording of information such
as injections and AEs.
At W eek 2, a telephone call was made by a nurse to
monitor device use by the patient and to collect informa-
tion on AEs and concomitant medications. Further
assessments were made at Weeks 4, 8 and 12. The Patient
User Trial Questionnaire was completed at Weeks 4 and
12. The MSTCQ was completed and safety data collected
at Weeks 4, 8 and 12. Local tolerability following injection
was assessed at the follow-up visits by direct questioning
of the patient and assessment of patient diaries.
Trainers (defined as the person who presents the
patient with the device, trains them in device use and fol-
lows up during the study) evaluated the device by com-
pleting the Trainer User Trial Questionnaire at SD1 and
Week 12, giving feedback on topics that included device
functionality and ease of use.
Study endpoints
Primary endpoint
The primary endpoint was the proportion of patients
with relapsing MS rating the new device as 'very suitable'
or 'suitable' for self-injecting the new formulation of sc
IFN beta-1a at the end of the 12-week treatment period.
Secondary endpoints
Secondary endpoints included the incidence of pre-
defined ISRs leading to treatment discontinuation at the
end of Week 12 and evaluation of the injection process,
treatment differences, and overall injection issues at
Weeks 4, 8 and 12 using the MSTCQ. This evaluation
included MSTCQ subscale scores for 'flu-like' symptoms
(FLS), ISRs, global side-effects (GSE), and the most
important benefit of the device (at SD1 and Weeks 4, 8
and 12). Injection pain was assessed using the short-form
McGill Pain Questionnaire, visual analogue scale (VAS),
and rating of pain (at SD1 and Weeks 4, 8 and 12). Overall
evaluation of the device was based on responses from the
Patient and Trainer User Trial Questionnaires (at SD1
and Weeks 4 and 12).
Safety endpoints
Safety endpoints included the incidence of treatment-
emergent AEs, including serious AEs and abnormal labo-
ratory parameters. According to the monitoring conven-
tion, only ISRs leading to treatment discontinuation were
recorded as AEs. Other reactions at the injection site
relating to sc IFN beta-1a administered using the new
device were recorded on the local tolerability form as part
of regular physician follow-up.
Analysis populations
The intent-to-treat (ITT) population comprised all
patients who had received at least one injection using the
device and, for the primary endpoint, had a valid baseline
and Week 12 assessment of device use. The per-protocol
(PP) population was as for the ITT population, but
e x c l u d e d  p a t i e n t s  w i t h  m a j o r  p r o t o c o l  v i o l a t i o n s .  T h e
safety population included all patients with follow-up
safety data who had received at least one administration
of study medication.
Statistical analyses
For the primary endpoint, a sample of 100 patients was
considered satisfactory to test the functionality and suit-
ability of the new device. For the secondary endpoint
(proportion of patients experiencing ISRs at the end of 12
weeks of treatment), a sample of 100 patients was
required to determine a proportion of 28% (based on a
post hoc analysis of data from a previous study) with a
precision of 8-9%, using a 95% confidence interval (CI).
Descriptive statistics were calculated for continuous
and categorical variables. No formal comparisons of data
over time were performed. For the primary endpoint, the
percentage of patients and corresponding exact 95% CIs
(based on the Clopper-Pearson formula) were calculated;
descriptive and inferential methods were used for sec-
ondary endpoints.Devonshire et al. BMC Neurology 2010, 10:28
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The primary endpoint was analysed only for patients
with complete assessments at baseline and Week 12. A
sensitivity analysis was conducted on the primary end-
point for the ITT population in which patients with miss-
ing data were assigned to the worst suitability category
('not at all suitable'), thereby including them in the
denominator for the calculation. MSTCQ items related to
FLS, ISRs and GSE subscales were imputed as stated in
the MSTCQ scoring manual. Other missing data, includ-
ing the primary endpoint, were not imputed.
Results
Patient disposition
Of the 108 patients screened, 106 were enrolled (ITT
population). The two patients who failed screening did
not meet the eligibility criteria. Of the 106 enrolled
patients, 101 (95.3%) completed the 12 weeks of on-study
treatment. Four of the five patients who withdrew from
treatment did so between SD1 and Week 4. Reasons for
premature treatment withdrawal were AEs (four patients)
and protocol violation (one patient). Ten patients (9.4%)
had at least one major protocol deviation and were
excluded from the PP population. Major protocol devia-
tions were: less than 75% compliance during the study
(four patients; 3.8%); missing the Week 12 Patient User
Trial Questionnaire (four patients; 3.8%); and inclusion
criteria not met (two patients; 1.9%).
Patient demographics
Baseline patient demographics are shown in Table 1.
Consistent sc IFN beta-1a therapy for at least 6 weeks
prior to screening was a requirement of study entry and,
notably, 86 of the 106 enrolled patients (81.1%) had been
taking sc IFN beta-1a for at least 1 year before starting the
study.
Trainer population
The trainer population comprised one trainer from each
participating centre (i.e. 15 trainers in total).
Suitability of the device for self-injection of sc IFN beta-1a
At the end of Week 12, 71.6% (95% CI: 61.8%, 80.1%; 73/
102) of patients found the new device to be 'very suitable'
or 'suitable' for self-injection of sc IFN beta-1a (primary
endpoint). Furthermore, 92.2% of patients reported some
degree of suitability ('very suitable', 'suitable' or 'a little
suitable'). Only 7.8% found the new device to be 'not at all
suitable' for self-injection (Figure 1).
Sensitivity analyses, in which imputation of missing
values was conducted by assigning patients with missing
data to the worst suitability category ('not at all suitable')
supported this finding: 68.9% (95% CI: 59.1%, 77.5%; 73/
106) of patients found the new device to be 'very suitable'
or 'suitable' for self-injection at Week 12.
Evaluation of the injection process
The study was not designed to compare the new device
with patients' previous experience of self-injection meth-
ods. However, certain items of the MSTCQ (administered
at 4-week intervals) do assess changes in patients' experi-
ence of the injection process by recording feedback on
injections in the last 4 weeks. For items 24 to 33 on the
MSTCQ at Weeks 4, 8 and 12, the majority of patients
reported that the process of performing injections with
the new device over the previous 4 weeks (e.g. prepara-
tion, clean up, making injections, injection-related pain,
time taken, ease of use of the system, FLS, and occurrence
of injection reactions) was equivalent to, or compared
favourably with, their previous experience of self-injec-
tion (Additional file 1).
Only minor changes were seen over time in parameters
relating to the procedure of performing injections with
the new device. For most of these parameters, the pro-
portions of patients reporting their experience over the
last 4 weeks as being at least equivalent to their previous
experience with this device were slightly higher at Week
12 than at Week 4. Interestingly, the proportion of
patients reporting that the injection procedure took less
or about the same time increased from 56.3% at Week 4
to 76.2% at Week 12. Most patients found local injection
reactions and pain (as assessed using the MSTCQ) to be
equivalent or less problematic than previously, and there
was little change in these measures over the duration of
the study. At both Weeks 4 and 12, patients reported no
change in overall injection issues and side-effects in the
previous 4 weeks (data not shown).
Overall device evaluation
A t  W e e k  1 2 ,  e a c h  o f  t h e  d e v i c e  f e a t u r e s  ( d i s p l a y  o f
remaining doses in cartridge, display of last injection date
and time, audible and visual signals, confirmation of end
of injection, dose history, teach-me menu, on-screen
instructions, pre-programmed dose, and skin sensor) was
rated as 'useful' or 'very useful' by over 80% of patients;
ratings for each feature are show in Figure 2. Further,
95.2% (99/104) of patients rated the use of device func-
tions, generally, as 'very easy' or 'easy'. Each of the device
actions (needle attachment, injection, needle detach-
ment, cartridge change) was rated as 'easy' or 'very easy'
to perform by over 80% of patients. Based on their experi-
ence, most patients rated 'overall convenience' to be the
most important benefit of the new device (from a pre-
defined list of responses) at all time points, reported by
63 of 85 respondents (74.1%) at Week 12.
At the end of Week 12, 71.2% (74/104) of patients rated
the new device equal to or more convenient than their
current device and 60.2% (62/103) of patients reportedDevonshire et al. BMC Neurology 2010, 10:28
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that they would prefer to keep the new device than revert
to using their previous device.
All 15 trainers (100%) rated the device and device func-
tions as 'easy' or 'very easy' to use.
Comfort settings
By Week 12, 60.6% (63/104) of patients had changed the
comfort settings on the device from baseline. For each
comfort setting (needle speed, and injection speed, depth
and time), a range of different settings were used by the
63 patients who changed these during the study.
Tolerability of sc IFN beta-1a administered using the new 
device
Local reactions at the injection site following self-injec-
tion (pain, swelling, redness or bruising), as reported by
Table 1: Baseline patient demographics, disease characteristics and treatment history.
Characteristic Intent-to-treat population
Age, years n (missing) 106 (0)
Mean (SD) 41.7 (9.3)
Median (range) 40.2 (23-63)
Sex, n (%) Male 41 (38.7)
Female 65 (61.3)
Race, n (%) White 103 (97.2)
Black 1 (0.9)
Other 2 (1.9)
IFN beta-1a (sc) treatment before 
switching to new formulation of IFN beta-
1a (sc)
n (missing) 106 (0)
Yes 97 (91.5)
No 9 (8.5)
Time from first IFN beta-1a (sc) treatment, 
years
n (missing) 97 (0)
Mean (SD) 3.76 (2.54)
Median (range) 3.20 (0.4-14.8)
Time from first IFN beta-1a (sc) treatment, 
n (%)
<6 months 3 (3.1)
6 months-1 year 8 (8.2)
1-2 years 16 (16.5)
>2 years 70 (72.2)
Time from first treatment with new 
formulation of IFN beta-1a (sc), years
n (missing) 105 (1)
Mean (SD) 0.73 (0.38)
Median (range) 0.61 (0.2-1.4)
EDSS score n (missing) 106 (0)
Mean (SD) 2.2 (1.57)
Median (range) 2.0 (0.0-6.5)
EDSS category, n (%) 0-<1 11 (10.4)
1-<2 34 (32.1)
1-<3 33 (31.1)
3-<4 13 (12.3)
4-<5 6 (5.7)
5-<6 1 (0.9)
≥6 8 (7.5)
EDSS, Expanded Disability Status Scale; IFN, interferon; sc, subcutaneous; SD, standard deviation.Devonshire et al. BMC Neurology 2010, 10:28
http://www.biomedcentral.com/1471-2377/10/28
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Figure 1 Patient-rated suitability of the new device for self-injection of the new formulation of subcutaneous interferon beta-1a at Week 
12: intent-to-treat population (n = 102, 4 missing).
Figure 2 Proportion of patients reporting device features as 'useful' or 'very useful' at Week 12 (n = 104 except for 'pre-programmed dose' 
[n = 103]).Devonshire et al. BMC Neurology 2010, 10:28
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patients during follow-up visits and recorded by the phy-
sician on the local tolerability report form, occurred in 79
(74.5%) patients over the 12 weeks. Most reactions were
considered mild or moderate in severity (Figure 3). Mini-
mal changes in side-effects relating to ISRs in the previ-
ous 4 weeks (assessed via the MSTCQ) were reported by
patients between SD1, which assessed the period when
patients were using their previous injection device, and
Week 12, which assessed their experience with the new
device (Table 2). Similarly, there was little change over
time in MSTCQ side-effect scores relating to FLS and
GSE in the previous 4 weeks between SD1 and Week 12
(Table 2).
Pain on injection, as assessed using the Pain Rating
Grade and Pain Rating Scale (VAS), did not differ
between Weeks 4 and 12 (data not shown). Over half of
the patients reported no or only mild pain on injection on
the Pain Rating Grade from Week 4 (61.4%; 62/101) to
Week 12 (56.6%; 60/106). There were no clear differences
between SD1 and Week 12 in injection-related pain, as
as se s sed  b y  t h e  M c G i l l  P a i n  Qu e s t i o n n a i r e .  M os t  pa i n
symptoms were reported as absent by more than 70% of
patients at both SD1 and Week 12.
Safety
No new or unexpected safety issues associated with expo-
sure to sc IFN beta-1a were observed during this study.
Serious AEs occurred in three (2.8%) patients. AEs are
s u m m a r i z e d  i n  T a b l e  3 .  P r e s p e c i f i e d  I S R s  l e a d i n g  t o
treatment withdrawal occurred in four (3.8%) patients.
Some patients discontinued treatment because they had
experienced more than one AE. Four patients (3.8%)
experienced AEs that led to permanent, premature dis-
continuation of treatment: injection-site pain (n = 3),
injection-site erythema (n = 2), injection-site irritation (n
= 2) and influenza-like illness (n = 1).
Discussion
The RebiSmart™ User Trial investigated the feasibility of
the new electronic injection device to self-inject sc IFN
beta-1a in patients with relapsing MS, primarily by
assessing patient-rated suitability of the device and evalu-
ation of the device and the injection process. Over 90% of
patients in this study reported some degree of suitability
and 71.6% considered the device 'suitable' or 'very suit-
able' for this purpose. The sensitivity analysis, which con-
sidered the worst-case scenario by assigning missing
patients to the 'not at all suitable' category, supported this
finding.
No new safety concerns were raised in this study; sc
IFN beta-1a was generally well tolerated, with the AEs
being consistent with the known safety profile of this
drug [5,16]. As expected, there was little difference in the
incidences of FLS and local ISRs throughout the study,
indicating that AEs were largely unaltered by a change in
injection device. Importantly, overall injection issues did
not change notably, and side-effects relating to sc IFN
beta-1a self-administration using the new device gener-
ally remained stable over the 12-week study.
Injection devices have been shown to reduce ISRs [14],
at least partly by ensuring correct injection technique. As
ISRs are probably related more to the study drug than the
device, the little or no change in local tolerability seen
over the course of this study was as expected. Notably
only four patients (3.8%) experienced prespecified ISRs as
an AE, all of which occurred within the first 4 weeks of
the study. Patient-reported local reactions at the injection
site, as recorded by physicians on the local tolerability
Figure 3 Local tolerability of injections during 12-week study period (safety population, n = 106).Devonshire et al. BMC Neurology 2010, 10:28
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report form (including redness, pain, bruising or itching),
occurred in 74.5% of patients over the 12 weeks. How-
ever, 75.2% stated that ISRs did not interfere at all with
daily work and activities (data not shown).
Injection-related pain, recorded through various
assessment tools, generally did not change over the
course of the study. Pain on injection was given as a rea-
son for changing comfort settings, but at the time of the
trial there was no available information on optimum
comfort settings in different patient groups. As it was not
possible to provide patients with guidance on setting
algorithms, it is presumed that patients had to e xperi-
ment with different settings before finding their most
comfortable injection settings. Over such a short (12-
week) study, without guidelines, patients may not have
felt confident in changing the settings despite being
trained in this device function, which may explain why
40% made no changes at all. Thus, patients may not have
found their optimum settings. Further studies are needed
to determine optimum comfort settings in different
patients.
As with other ISRs, pain is probably not related to the
device. At the time of the study, refrigerated storage of
the new formulation in the multi-dose cartridge was nec-
essary, and injection of the drug that was below room
temperature may have resulted in ISRs, including pain. It
is possible that patients familiar with the single-dose
syringe may have underestimated the time needed to
warm the larger volume of drug in the multi-dose car-
tridge within the device to room temperature. In addi-
tion, while patients were advised to keep the solution out
of the fridge for 1 hour prior to injection, this may have
been insufficient for the solution to reach room tempera-
ture in some situations. Indeed, it is possible that no dis-
continuations due to AEs occurred after 4 weeks at least
partly because patients were more practiced in the entire
injection process, including the time required to warm
the drug to room temperature in their surroundings.
However, as detailed information on injection prepara-
tion was not formally collected, we cannot confirm that
injection of cold drug contributed to the relatively high
incidence of ISRs seen in this study. Correct injection
preparation can be addressed through patient education
Table 2: MSTCQ scores for subscales relating to injection-site reactions (ISRs), 'flu-like' symptoms (FLS), and global side-
effects (GSE), by 4-week interval.
ISR score* FLS score* GSE score*
Time point Observed Change Observed Change Observed Change
Study Day 1 n (missing) 106 (0) - 106 (0) - 106 (0) -
Mean (SD) 11.1 (3.3) - 9.5 (3.7) - 4.8 (1.7) -
Median 11.0 - 10.0 - 4.0 -
(range) (4-19) (4-17) (3-10)
W e e k  4 n  ( m i s s i n g ) 1 0 3  ( 3 )1 0 3  ( 3 )1 0 3  ( 3 )1 0 3  ( 3 )1 0 3  ( 3 )1 0 3  ( 3 )
Mean (SD) 11.4 (3.2) 0.3 (3.3) 8.8 (3.9) -0.7 (3.3) 5.5 (2.4) 0.7 (2.3)
Median 12.0 0.0 9.0 0.0 5.0 0.0
(range) (4-18) (-10-9) (4-17) (-9-10) (3-13) (-4-9)
W e e k  8 n  ( m i s s i n g ) 1 0 0  ( 6 )1 0 0  ( 6 )1 0 0  ( 6 )1 0 0  ( 6 )1 0 0  ( 6 )1 0 0  ( 6 )
Mean (SD) 11.3 (3.5) 0.2 (3.6) 8.8 (3.8) -0.8 (3.0) 5.2 (2.2) 0.5 (2.2)
Median 12.0 0.0 9.0 0.0 5.0 0.0
(range) (4-18) (-11-8) (4-17) (-11-8) (3-12) (-4-7)
Week 12/
early 
termination
n  ( m i s s i n g ) 1 0 6  ( 0 )1 0 6  ( 0 )1 0 6  ( 0 )1 0 6  ( 0 )1 0 6  ( 0 )1 0 6  ( 0 )
Mean (SD) 11.4 (3.4) 0.3 (3.4) 9.0 (3.8) -0.5 (3.3) 5.6 (2.6) 0.8 (2.5)
Median 12.0 0.0 9.0 0.0 5.0 0.0
(range) (4-19) (-11-8) (4-18) (-7-11) (3-14) (-4-9)
MSTCQ, Multiple Sclerosis Treatment Concern Questionnaire; SD, standard deviation.
*Maximum score = 20 for ISR and FLS, 15 for GSE; higher scores indicate greater negative impact. Further information on the use of the MSTCQ 
to assess satisfaction with injection systems for subcutaneous interferon beta-1a can be found in [13].Devonshire et al. BMC Neurology 2010, 10:28
http://www.biomedcentral.com/1471-2377/10/28
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and support, but it should be noted that since completing
the study, approval has been granted for room tempera-
ture storage of the multi-dose cartridge for up to 2 weeks
[17], making refrigeration of the pre-loaded device no
longer necessary.
The positive findings of this study must be considered
in the context of the study limitations. Although the
Patient User Trial Questionnaire was used previously to
assess the suitability of a similar device in children and
adolescents requiring growth hormone therapy, this
questionnaire has not yet been validated in an adult, MS
population. Furthermore, patients may have found the
assessment of 'device suitability' difficult to interpret,
particularly with respect to differences between 'suitable'
and 'a little suitable'. Problems with interpretation may
have been confounded by translation of 'suitability' into
different languages. The inclusion of a defined patient
subgroup only may also have influenced results.
The finding that the majority of this population of
patients with relapsing MS considered the device to be
suitable for their use is particularly encouraging consider-
ing that over 80% had been receiving IFN beta-1a therapy
for over 1 year at study entry (the mean time since start-
ing sc IFN beta-1a treatment was 3.76 years), and all
patients had previous experience with autoinjector tech-
nologies. It is possible that changes to injection practice
might result in lower satisfaction with treatment in
patients who are already comfortable with their existing
administration method, particularly over the relatively
short duration of this 12-week study. Therefore, this
study population may be an appropriately stringent group
of patients in which to assess responses to a new injection
device.
It is reasonable to speculate that patients who are naïve
to, or who have discontinued treatment due to, injection-
related issues may perceive a greater benefit in a new
device. Nonetheless, even in the current study popula-
tion, the device was generally well received, with over
80% of patients rating the various device features as 'use-
ful' or 'very useful' and more than 95% considering the
Table 3: Adverse events (AEs) reported during the 12-week study (safety population).
Patients, n (%)
(n = 106)
Events, n (%)
(n = 193)
Treatment-emergent AE
Any 67 (63.2) 193 (100.0)
Influenza-like illness* 22 (20.8) 54 (28.0)
Headache* 12 (11.3) 25 (13.0)
Severity of treatment-emergent AEs
Mild 43 (40.6) 96 (49.7)
Moderate 35 (33.0) 73 (37.8)
Severe 14 (13.2) 24 (12.4)
Prespecified AEs
Any 32 (30.2) 74 (38.3)
'Flu-like' symptoms 22 (20.8) 54 (28.0)
Cytopenia 5 (4.7) 9 (4.7)
Injection-site reactions 4 (3.8) 8 (4.1)
Hypersensitivity 2 (1.9) 3 (1.6)
Rash (pruritus) 1 (0.9) 2 (1.0)
Serious AEs
Any 3 (2.8) 6 (3.1)
Myocardial infarction 1 (0.9) 1 (0.5)
Adverse drug reaction 1 (0.9) 1 (0.5)
Biliary colic 1 (0.9) 1 (0.5)
Breast infection 1 (0.9) 1 (0.5)
Seroma 1 (0.9) 1 (0.5)
Hypertensive crisis 1 (0.9) 1 (0.5)
*Most common (occurring in >10% of patients).Devonshire et al. BMC Neurology 2010, 10:28
http://www.biomedcentral.com/1471-2377/10/28
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d e v i c e  f u n c t i o n s  a s  ' e a s y '  o r  ' v e r y  e a s y '  t o  p e r f o r m .
Indeed, at the end of the study, 60.2% of patients stated
that they would prefer to continue using the new device
than to return to their previous device. This proportion
might seem low considering that very few patients dis-
continued treatment over the study period and over half
considered the device to be more convenient than their
previous device. However, it is possible that this finding
may reflect a desire by a proportion of patients to return
to an injection device with which they had experience
outside of the clinical trial environment. In addition, the
findings of this 12-week study suggested that a 'learning
curve' existed even over this relatively short time-period,
with patients becoming more adept at using the device
over time. The proportion of patients who found overall
convenience to be the most important benefit of the
device increased from 42.2% at SD1 to 74.1% at Week 12,
a n d  t h e  p e r c e n t a g e  o f  p a t i e n t s  w h o  r e p o r t e d  t h a t  a
shorter or similar amount of time was needed for the pro-
c e d u r e  t h a n  p r e v i o u s l y  r o s e  f r o m  5 6 . 3 %  a t  W e e k  4  t o
76.2% at Week 12. Responses for other MSTCQ items
relating to performing injections also tended to become
more positive over time, suggesting that patients were
becoming more proficient in preparing and performing
injections with the new device. The proportion of
patients wishing to continue using the new device may
therefore have increased with prolonged use.
Despite patient awareness of the potentially debilitating
nature of MS, long-term adherence to therapy is known
to be poor [10]. Failure to adhere to prescribed treatment
can have several consequences, including reduced effi-
cacy, increased healthcare costs and poor long-term
health outcomes. Among the many factors that can lead
to treatment discontinuation [9], anxiety and concerns
over self-injection are strong predictors of treatment dis-
continuation after 6 months [8]. Adherence to therapy
[18,19] and shorter treatment gaps [11] have been shown
to decrease the risk of severe relapse in patients with MS
receiving DMD therapy. Improving treatment adherence
is, therefore, an important goal.
Delivery devices have the potential to help patients
overcome injection-related problems, such as ISRs and
fear of incorrect injection technique, which may improve
adherence. Indeed, the use of injection devices can sub-
stantially reduce ISRs compared with injection with
syringe alone [14], and improvements in device technol-
ogy have been shown to reduce ISRs and pain on injec-
tion, and improve treatment satisfaction [13]. In addition
to shielding the needle from view and improved conve-
nience, which are benefits common to all currently avail-
able injection devices, the new electronic injection device
has several specific additional features that may further
benefit patients. The ability to adjust injection comfort
settings may encourage patients to experiment with new
settings and customize these to their personal prefer-
ences. This function may enable patients to continue
therapy where they may previously have chosen to stop
treatment. Additionally, over 90% of patients considered
confirmation of successful injection to be useful in pro-
viding reassurance that they had administered their injec-
tions correctly. The multi-dose cartridge contains 1
week's worth of medication, which reduces the frequency
of device loading. The novel dosing log informs the
patient that an injection is due and serves as a reminder
of treatment history, which may be particularly useful to
patients with cognitive impairment. The log also enables
adherence to MS treatment to be recorded accurately and
objectively for the first time. In contrast, all previous
measures of adherence have relied on subjective, often
retrospective, patient reporting, which can give inaccu-
rate results. Dosing history data can also be downloaded,
linked to electronic patient records and reviewed by phy-
sicians, and thus may promote an open dialogue between
patient and neurologist regarding treatment adherence,
although this was not assessed in this study. Furthermore,
as adherence to treatment can influence outcomes,
assessment of efficacy in both trials and in the clinic may
be confounded by the patient's subjective reporting of
adherence. Hence, a device that can provide an objective
measure of adherence may also be a critical tool in assess-
ing the true relationship of treatment to patient out-
comes. Treatment adherence in patients using the device
is currently being assessed in an ongoing study being car-
ried out in Canada (Study EMR701068_520). In addition,
it may be interesting to compare treatment adherence
and disease outcomes in patients using the new device
and in those using other delivery methods.
Conclusions
This study gave patients with relapsing MS who had been
consistently self-administering sc IFN beta-1a for at least
6 weeks prior to the study the opportunity to test and
assess the suitability of a new electronic injection device
for self-injection of their current therapy. The vast major-
ity of patients in the study considered the new device to
be suitable for the self-administration of sc IFN beta-1a
for the treatment of relapsing MS (over 90% of patients
reported some degree of suitability). In addition, the
device was found to be easy to use and to have features
considered useful by most patients. Most patients also
found using the new device either equivalent to or better
than their previous experience for a range of measures
relating to the injection procedure, and over half wanted
to continue using the device at the end of the study. Based
on these findings, it is reasonable to predict that the
device may also be suitable for those who are not satisfied
with existing administration methods or those new to
DMD therapy. Furthermore, the benefits and device fea-
tures may help patients to adhere to their prescribed
therapy and provide a basis for discussions betweenDevonshire et al. BMC Neurology 2010, 10:28
http://www.biomedcentral.com/1471-2377/10/28
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patients and physicians in order to optimize adherence
and so maximize outcomes with chronic treatment for
MS.
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